A new eye drop used in conjunction with anti-angiogenic treatments such as Lucentis or Avastin might significantly improve their action.
Results from trials on chick embryos have shown that OT-551 applied topically has a synergistic effect with the intraocular anti-angiogenic drug and reduces new vessel response further than if the anti-angiogenic was used alone.
Dr Shaker Mousa, heading the research team working for Othera Pharmaceuticals at the Albany College of Pharmacy, said 'these results demonstrate that OT-551 could potentially improve the outcome of patients already on Lucentis so decreasing the need for frequent Lucentis injections.'
As the trials move to Phase II testing, Mousa, speaking at the Angiogenesis 2007 Conference in Florida, also stated how Othera were to initiate Phase II trials investigating the use of OT-551 in treating atrophic AMD.
A new eye drop used in conjunction with anti-angiogenic treatments such as Lucentis or Avastin might significantly improve their action.